Jula Inrig, M.D.

Jula Inrig, M.D.

Chief Medical OfficeratTravere Therapeutics· In proxies 2022–2025

Pay in FY2025Travere Therapeutics stock +119.3% the same year

Jula Inrig, M.D. was paid $3.0M in FY2025 (Dec). Travere Therapeutics stock rose 119.3% that year.

Pay$100 in the stock at the end of FY21 → $64
Pay is from the Summary Compensation Table of each Travere Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Travere TherapeuticsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role +63%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?